Literature DB >> 8434651

Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes.

J Garrigues1, U Garrigues, I Hellström, K E Hellström.   

Abstract

BR96 is a monoclonal antibody (MAb) that recognizes many human carcinomas and can kill antigen-positive tumor cells in vitro. Using both gold and radiolabeled MAb, the distribution and cellular processing of BR96 during cytolysis has been determined. After a brief (< 3 minutes) MAb treatment, cells in suspension are stained by the nuclear viability dye propidium iodide. Whole MAb and F(ab')2 fragments are equally cytotoxic; monovalent F(ab) fragments, however, have no effect on dye uptake unless cross-linked with goat anti-mouse IgG. The level of toxicity is dependent on both MAb dose and on cell surface receptor density. Cell contact may regulate receptor expression. BR96 receptors are more abundant on cells migrating into the open areas of a scratch wounded confluent culture than on the adjacent contact-inhibited cells. BR96 can also inhibit the anchorage-independent growth of tumor cells in soft agar showing that its effects on propidium iodide staining are not due to transient changes in membrane permeability. Immunogold electron microscopy reveals that, after a 1-minute treatment, BR96 induces significant infolding of the plasma membrane and that internalized MAb is localized to these structures. Immediately thereafter, large cell surface and intracellular vesicles form, mitochondria are swollen, and membrane integrity is lost. Therefore, BR96 seems to cause morphological changes characteristic of necrosis rather than apoptosis. When bound to adherent carcinoma cells, BR96 is distributed uniformly on the apical surface of cells labeled at 4 C and is enriched at points of cell substratum contact. Upon warming of the cells to 37 C, BR96 localizes in small perinuclear clusters and the cell margin is now devoid of label. Immunogold electron microscopy reveals that BR96 undergoes receptor mediated internalization and is localized within the same coated pits, endosomes, and lysosomes as the transferrin receptor. Quantitative studies using iodinated BR96 show that after 6 hours of chase, a maximum of 53% of the radiolabel is located within the intracellular pool. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicates that 84% of this fraction is nondegraded. BR96 probably cycles between the medium and intracellular pools because the remainder of the radiolabel is in the medium as intact MAb. By 24 hours of chase, the intracellular fraction drops to 30%, while the remaining 70% is present in the culture medium, mostly as low molecular weight degradation products.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8434651      PMCID: PMC1886722     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures.

Authors:  C A Smith; G T Williams; R Kingston; E J Jenkinson; J J Owen
Journal:  Nature       Date:  1989-01-12       Impact factor: 49.962

2.  Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens.

Authors:  I Hellström; H J Garrigues; U Garrigues; K E Hellström
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

3.  Movement of internalized ligand-receptor complexes along a continuous endosomal reticulum.

Authors:  C R Hopkins; A Gibson; M Shipman; K Miller
Journal:  Nature       Date:  1990-07-26       Impact factor: 49.962

4.  Functional role of HLA class I cell-surface molecules in human T-lymphocyte activation and proliferation.

Authors:  D S Taylor; P C Nowell; J Kornbluth
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

5.  Monoclonal antibody-mediated tumor regression by induction of apoptosis.

Authors:  B C Trauth; C Klas; A M Peters; S Matzku; P Möller; W Falk; K M Debatin; P H Krammer
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

Review 6.  Patterns of cell death.

Authors:  N I Walker; B V Harmon; G C Gobé; J F Kerr
Journal:  Methods Achiev Exp Pathol       Date:  1988

7.  TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins.

Authors:  R Oren; S Takahashi; C Doss; R Levy; S Levy
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

Review 8.  Molecular changes in carbohydrate antigens associated with cancer.

Authors:  A Singhal; S Hakomori
Journal:  Bioessays       Date:  1990-05       Impact factor: 4.345

9.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

Authors:  J A Drebin; V C Link; D F Stern; R A Weinberg; M I Greene
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

10.  Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor.

Authors:  T Espevik; M Brockhaus; H Loetscher; U Nonstad; R Shalaby
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

View more
  8 in total

1.  Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.

Authors:  Shui-On Leung; Kai Gao; Guang Yu Wang; Benny Ka-Wa Cheung; Kwan-Yeung Lee; Qi Zhao; Wing-Tai Cheung; Jun Zhi Wang
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.

Authors:  Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Dayson M Friaça; Ernesto S Nakayasu; Igor C Almeida; Renato A Mortara; Jacqueline F Jacysyn; Gustavo P Amarante-Mendes; Walter Magliani; Stefania Conti; Luciano Polonelli; Luiz R Travassos
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

3.  4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis.

Authors:  A E Koch; B J Nickoloff; J Holgersson; B Seed; G K Haines; J C Burrows; S J Leibovich
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

Review 4.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

5.  Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.

Authors:  S Silletti; S Paku; A Raz
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

6.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

Authors:  E Hurwitz; I Stancovski; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

7.  Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.

Authors:  Philip Noble; Ian Spendlove; Stephen Harding; Tina Parsons; Lindy G Durrant
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

8.  Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes.

Authors:  J Garrigues; J Anderson; K E Hellström; I Hellström
Journal:  J Cell Biol       Date:  1994-04       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.